Search alternatives:
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
e decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 761 - 780 results of 232,367 for search '(( 2 e decrease ) OR ( 10 ((((mean decrease) OR (nn decrease))) OR (a decrease)) ))', query time: 1.89s Refine Results
  1. 761
    PCA2 decreased LPS-induced ROS generation.

    PCA2 decreased LPS-induced ROS generation. by Qin-Qin Wang (9211958)

    Published 2020
    Save to List
    Saved in:
  2. 762
    Bacterial load in lung and spleen of binge-drinking mice intranasally infected with decreasing doses of <i>B</i>. <i>thailandensis</i>.

    Bacterial load in lung and spleen of binge-drinking mice intranasally infected with decreasing doses of <i>B</i>. <i>thailandensis</i>. by Victor M. Jimenez Jr. (8107853)

    Published 2019
    Save to List
    Saved in:
  3. 763
    Decreased F4/80<sup>+</sup> macrophages in the presence of PLD inhibitors using IF microscopy of lung sections.

    Decreased F4/80<sup>+</sup> macrophages in the presence of PLD inhibitors using IF microscopy of lung sections. by Karen M. Henkels (3350273)

    Published 2016
    “…(<b>A,A’,E</b>) Tissues from non-xenographed controls; (<b>B,B’,F</b>) from Xenotransplanted controls with Alzet pumps delivering vehicle; (<b>C,C’,G</b>) Xenotransplanted with Alzet pumps delivering vehicle FIPI or (<b>D,D’,H</b>) VU0155072-2. …”
    Save to List
    Saved in:
  4. 764
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  5. 765
    Decreased Ly6G<sup>+</sup> neutrophils in the presence of PLD inhibitors using IF microscopy of lung sections.

    Decreased Ly6G<sup>+</sup> neutrophils in the presence of PLD inhibitors using IF microscopy of lung sections. by Karen M. Henkels (3350273)

    Published 2016
    “…(<b>A,A’,E</b>) Tissues from non-xenographed controls; (<b>B,B’,F</b>) from Xenotransplanted controls with Alzet pumps delivering vehicle; (<b>C,C’,G</b>) Xenotransplanted with Alzet pumps delivering vehicle FIPI or (<b>D,D’,H</b>) VU0155072-2. …”
    Save to List
    Saved in:
  6. 766
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  7. 767
    Decreased proliferation of ErbB2<sup>+</sup>Ph<sup>+</sup>ALL cells is induced by ErbB inhibition.

    Decreased proliferation of ErbB2<sup>+</sup>Ph<sup>+</sup>ALL cells is induced by ErbB inhibition. by Mary E. Irwin (293687)

    Published 2013
    Save to List
    Saved in:
  8. 768
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  9. 769
    The recruitment of MYD88 to TLR2 and IRAK-4 phosphorylation are decreased in β3-integrin–silenced cells.

    The recruitment of MYD88 to TLR2 and IRAK-4 phosphorylation are decreased in β3-integrin–silenced cells. by Tatiana Gianni (499634)

    Published 2014
    Save to List
    Saved in:
  10. 770
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  11. 771
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  12. 772
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  13. 773
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  14. 774
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  15. 775
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  16. 776
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  17. 777
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  18. 778
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  19. 779
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  20. 780
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:

Search Tools: